Table 3 Univariate and multivariate analyses of outcomes in the < 75-year-old group
Univariate analysis | Multivariate analysis | |||||
Primary endpoint | OR (95% CI) | p value | OR (95% CI) | p value | ||
Atrial fibrillation | 0.36 (0.18–0.71) | 0.003 | 0.28 (0.13–0.62) | 0.001 | ||
CRT-D | 2.39 (0.85–6.70) | 0.09 | ||||
Male sex | 2.39 (0.85–6.70) | 0.09 | ||||
CKD | 0.53 (0.26–1.07) | 0.08 | ||||
Ivabradine | 2.25 (0.85–5.97) | 0.10 | ||||
NYHA ≥III | 1.74 (0.89–3.41) | 0.11 | 2.09 (0.95–4.59) | 0.07 | ||
QRS < 130 ms | 0.51 (0.21–1.24) | 0.13 | ||||
QRS > 150 ms | 1.63 (0.83–3.17) | 0.15 | ||||
Univariate analysis | Multivariate analysis (model 1 with atrial fibrillation) | Multivariate analysis (model 2 with anticoagulation) | ||||
One-year mortality | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value |
Atrial fibrillation | 23.68 (3.04–184.30) | < 0.001 | 14.35 (1.6–125.90) | 0.02 | ||
Rescue CRT | 17.48 (4.97–61.44) | < 0.001 | 14.32 (2.61–79.20) | 0.002 | 15.81 (3.35–75.10) | < 0.001 |
CRT-D | 0.11 (0.04–0.34) | < 0.001 | ||||
Beta-blockers | 0.16 (0.05–0.51) | 0.001 | ||||
CKD | 5.93 (1.61–21.83) | 0.003 | 5.96 (1.13–31.30) | 0.04 | 7.65 (1.47–39.61) | 0.02 |
Anticoagulation | 7.71 (1.68–33.26) | 0.003 | 5.32 (0.96–29.40) | 0.06 | ||
ACEI-ARB | 0.26 (0.09–0.78) | 0.01 | ||||
Diabetes mellitus | 2.86 (1.02–8.01) | 0.04 | ||||
Loop diuretics | 5.67 (0.72–44.56) | 0.07 | ||||
NYHA ≥III | 4.24 (1.16–15-48) | 0.02 | ||||
QRS > 150 ms | 0.46 (0.15–1.38) | 0.16 | ||||
Complications | 2.06 (0.69–6.08) | 0.19 | 4.20 (0.91–18.91) | 0.07 | ||